CytoSorbents(CTSO)
Search documents
CytoSorbents(CTSO) - 2021 Q3 - Earnings Call Transcript
2021-11-07 04:57
CytoSorbents Corporation (NASDAQ:CTSO) Q3 2021 Earnings Conference Call November 4, 2021 4:30 PM ET Company Participants Terri Powers - VP of IR & Corporate Communications Phillip Chan - CEO Christian Steiner - EVP of Sales & Marketing Efthymios Deliargyris - Chief Medical Officer Kathy Bloch - CFO Conference Call Participants Priya Sachdeva - SVB Leerink Bryan Bergin - Cowen Operator Good afternoon. And welcome to the CytoSorbents' Third Quarter 2021 Financial and Operating Results Conference Call. At thi ...
CytoSorbents(CTSO) - 2021 Q3 - Quarterly Report
2021-11-03 16:00
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36792 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 98-0373793 (State or other jurisdiction of (I.R.S. Empl ...
CytoSorbents(CTSO) - 2021 Q2 - Earnings Call Transcript
2021-08-04 02:56
CytoSorbents Corporation (NASDAQ:CTSO) Q2 2021 Earnings Conference Call August 3, 2021 4:30 PM ET Company Participants Terri Anne Powers - VP, IR and Corporate Communications Phillip Chan - Chief Executive Officer Efthymios Deliargyris - Chief Medical Officer Kathleen Bloch - Chief Financial Officer Christian Steiner - Executive Vice President, Sales and Marketing, Managing Director, CytoSorbents Europe GmbH Conference Call Participants Danielle Antalffy - SVB Leerink Anthony Petrone - Jefferies Andrew D'Si ...
CytoSorbents(CTSO) - 2021 Q2 - Quarterly Report
2021-08-02 16:00
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36792 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 98-0373793 (State or other jurisdiction of (I.R.S. Employer ...
CytoSorbents(CTSO) - 2021 Q1 - Earnings Call Transcript
2021-05-05 03:18
CytoSorbents Corporation (NASDAQ:CTSO) Q1 2021 Earnings Conference Call May 4, 2021 4:45 PM ET Company Participants Amy Vogel - Investor Relations Phillip Chan - Chief Executive Officer Efthymios Deliargyris - Chief Medical Officer Kathleen Bloch - Chief Financial Officer Christian Steiner - Executive Vice President, Sales and Marketing, Managing Director, CytoSorbents Europe GmbH Conference Call Participants Anthony Petrone - Jefferies Josh Jennings - Cowen Danielle Antalffy - SVB Leerink Andrew D'Silva - ...
CytoSorbents(CTSO) - 2021 Q1 - Quarterly Report
2021-05-03 16:00
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36792 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) 98-0373793 (State or other jurisdiction of (I.R.S. Employer Identifi ...
CytoSorbents(CTSO) - 2020 Q4 - Earnings Call Transcript
2021-03-10 06:00
Cytosorbents Corporation (NASDAQ:CTSO) Q4 2020 Earnings Conference Call February 9, 2021 3:15 PM ET Company Participants Amy Vogel – Investor Relations Phillip Chan – Chief Executive Officer Efthymios Deliargyris – Chief Medical Officer Kathleen Bloch – Chief Financial Officer Christian Steiner – Executive Vice President-Sales and Marketing and Managing Director-CytoSorbents Europe Gmbh Vincent Capponi – President and Chief Operating Officer Christopher Cramer – Vice President-Business Development Conferenc ...
CytoSorbents(CTSO) - 2020 Q4 - Annual Report
2021-03-08 16:00
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-36792 (Nasdaq Capital Market) Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-kn ...
CytoSorbents(CTSO) - 2020 Q3 - Earnings Call Transcript
2020-11-05 03:28
Cytosorbents Corporation. (NASDAQ:CTSO) Q3 2020 Earnings Conference Call November 4, 2020 4:45 PM ET Company Participants Phillip Chan - Chief Executive Officer Vincent Capponi - Chief Operating Officer and President Kathleen Bloch - Chief Financial Officer Efthymios Deliargyris - Chief Medical Officer Christian Steiner - Senior Vice President of Sales and Marketing from Germany Christopher Cramer - Vice President of Business Development Jeremy Feffer - LifeSci Advisors, Investor Relations Conference Call P ...
CytoSorbents(CTSO) - 2020 Q3 - Quarterly Report
2020-11-04 21:11
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 Or ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36792 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 98-0373793 (State or other jurisdiction of (I.R.S. Empl ...